Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6279964 | Neuroscience Letters | 2016 | 7 Pages |
Abstract
Intracerebral complement activation after severe traumatic brain injury (TBI) leads to a cascade of neuroinflammatory pathological sequelae that propagate host-mediated secondary brain injury and adverse outcomes. There are currently no specific pharmacological agents on the market to prevent or mitigate the development of secondary cerebral insults after TBI. A novel chimeric CR2-fH compound (mTT30) provides targeted inhibition of the alternative complement pathway at the site of tissue injury. This experimental study was designed to test the neuroprotective effects of mTT30 in a mouse model of closed head injury. The administration of 500 μg mTT30 i.v. at 1 h, 4 h and 24 h after head injury attenuated complement C3 deposition in injured brains, reduced the extent of neuronal cell death, and decreased post-injury microglial activation, compared to vehicle-injected placebo controls. These data imply that site-targeted alternative pathway complement inhibition may represent a new promising therapeutic avenue for the future management of severe TBI.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Megan C. Rich, Chesleigh N. Keene, Miriam D. Neher, Krista Johnson, Zhao-Xue Yu, Antoine Ganivet, V. Michael Holers, Philip F. Stahel,